Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclin D1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Cyclin D1 siRNA (also referred to as CyD1 siRNA or siCyD1) is a research-stage RNA interference (RNAi)-based therapeutic modality designed to silence the expression of Cyclin D1 (CyD1), a key cell cycle-regulatory protein encoded by the CCND1 gene. By degrading CyD1 mRNA, this small interfering RNA reduces Cyclin D1 protein levels, leading to the hypophosphorylation of retinoblastoma protein (RB) and subsequent cell cycle arrest in the G1 phase. Because Cyclin D1 is frequently overexpressed in various malignancies and inflammatory conditions, cyclin D1 siRNA has been investigated for the treatment of cancers, such as breast cancer and mantle cell lymphoma, as well as inflammatory diseases like colitis. Various delivery systems, including nanoliposomes and targeted stabilized nanoparticles (tsNPs) conjugated with antibodies (e.g., anti-β7 integrin), have been explored to improve its stability and cell-specific uptake.
- Other names
- CyD1 siRNACyD-1 siRNACyD 1 siRNAsiCyD1siCyD-1siCyD 1
02
Targets
CCND1 (Cyclin D1)
Beyond the preview
Go deeper on cyclin D1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclin D1 siRNA.